EXHIBIT 99.1

For Additional Information:
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com


CytRx Reports 2008 Financial Results

LOS ANGELES (March 13, 2009) CytRx Corporation
(NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today reported financial results for the 12 months ended December 31, 2008.

“We took major steps during the past year to build an oncology franchise,” said Steven A. Kriegsman, CytRx President and CEO.  “We added very promising oncology assets including acquiring the U.S. rights to tamibarotene, a third-line treatment for acute promyelocytic leukemia (APL) that is currently in a Phase 2 U.S. registration clinical trial.  We also further strengthened our oncology expertise with the addition of prominent experts in this field.  We believe we have the leadership and drug development pipeline to build a drug franchise with commercial and out-licensing possibilities.  With over $25 million of cash on our balance sheet as of December 31, 2008, and our 45% ownership position in RXi Pharmaceuticals Corporation (NASDAQ: RXII) with a market value of approximately $22.2 million as of March 10, 2009, we are well-positioned to focus on our development pipeline and consider in-licensing and acquisition opportunities that the current economic environment may present.

“We remain committed to our orally administered molecular chaperone regulator drug candidates, arimoclomol and iroxanadine, and our pursuit of partnering,” continued Mr. Kriegsman.

REVIEW OF FINANCIAL RESULTS
 
CytRx reported a net loss applicable to common stockholders for the 12 months ended December 31, 2008 of $27.8 million, or $0.30 per share, based on 91.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders for the 12 months ended December 31, 2007 of $21.9 million, or $0.26 per share, based on 84.0 million shares outstanding.  The 2008 net loss included a non-cash charge of approximately $8.0 million for in-process research and development related to the acquisition of Innovive Pharmaceuticals, Inc., or Innovive.  The increase in weighted average shares outstanding resulted primarily from the issuance of shares relating to the acquisition of Innovive.

Revenue for 2008 was $6.3 million, compared with 2007 revenue of $7.5 million, and consisted primarily of service revenue recognized from CytRx's 2006 royalty transaction with the ALS Charitable Remainder Trust, or ALSCRT.

Research and development (R&D) expenses were $10.5 million for the 12 months ended December 31, 2008, compared with $18.8 million for the comparable period in 2007.  R&D expenses incurred during 2008 were related primarily to the Company's various development programs and included two months of RXi-related expenses.  The significant reduction in R&D expenses for 2008 was due mainly to the full-year impact of RXi-related R&D expenses in 2007.

General and administrative (G&A) expenses were $10.9 million for 2008, compared with $14.8 million in the prior year.  The decrease in G&A expenses in 2008 resulted primarily from a reduction of approximately $3.3 million in RXi-related expenses and a reduction of $300,000 in legal and accounting fees as compared to 2007, offset by approximately $320,000 in professional fees associated with the acquisition of Innovive.

Cash and cash equivalents totaled $25.0 million as of December 31, 2008, compared with cash and cash equivalents of $60.4 million as of December 31, 2007, which included short-term investments of approximately $10.0 million held by RXi at the end of 2007.  For the year ended December 31, 2008, $7.0 million was used in investing activities, which included a cash outlay of $5.7 million relating to the payment of accounts payable associated with the acquisition of Innovive.  CytRx's 45% ownership stake in RXi at December 31, 2008 had a market value of approximately $36.0 million, and as of March 10, 2009, had a market value of approximately $22.2 million.
 
About CytRx Corporation
 
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics.  The CytRx drug development pipeline includes programs in clinical development for oncology indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL).  CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. The Company owns and operates a research and development facility in San Diego.  CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals Corporation (NASDAQ: RXII).  For more information on the Company, visit www.cytrx.com.
 
Forward-Looking Statements
 
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the timing, outcome or results of any pre-clinical or clinical testing of CytRx's potential oncology or molecular chaperone drug candidates, including tamibarotene as a third-line treatment for APL and INNO-206, risks related to CytRx’s ability to manufacture its drug candidates, including tamibarotene, in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's ability to enter into partnerships to advance the clinical development of INNO-406 and its clinical molecular chaperone portfolio, uncertainties related to the impact of the FDA's clinical hold on the Company's arimoclomol clinical trial for ALS on the timing and ability to resume clinical testing at the desired dosage of arimoclomol, the risk that any requirements imposed on the Company's planned clinical trial designs for ALS or stroke recovery by the FDA as a result of the concerns expressed in their clinical hold of the Company's ALS program might adversely affect the Company's ability to demonstrate that arimoclomol is efficacious in treating ALS or stroke patients or to enter into a partnership to advance the development of that drug candidate, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, risks related to the future market value of CytRx's investment in RXi and the liquidity of that investment, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 
 

The following information was filed by Cytrx Corp (CYTR) on Friday, March 13, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Cytrx Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cytrx Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account